PMID- 31771560
OWN - NLM
STAT- MEDLINE
DCOM- 20200429
LR  - 20200429
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 19
IP  - 1
DP  - 2019 Nov 27
TI  - Gender differences at presentation of idiopathic pulmonary fibrosis in Sweden.
PG  - 222
LID - 10.1186/s12890-019-0994-4 [doi]
LID - 222
AB  - BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a disease with poor prognosis 
      mainly affecting males. Differences in clinical presentation between genders may 
      be important both for the diagnostic work-up and for follow-up. In the present 
      study, we therefore explored potential gender differences at presentation in a 
      Swedish cohort of IPF-patients. METHODS: We studied patients included in the 
      Swedish IPF- registry over a three-year period from its launch in 2014. A 
      cross-sectional analysis was performed for data concerning demographics, lung 
      function, 6- min walking test (6MWT) and quality of life (QoL) (King's Brief 
      Interstitial Lung Disease (K-BILD) score). RESULTS: Three hundred forty- eight 
      patients (250 (72%) males, 98 (28%) females, median age 72 years in both genders) 
      were included in the registry during the study period. Smoking history (N = 169 
      (68%) vs. N = 53 (54%), p < 0.05), baseline lung function (Forced vital capacity, 
      % of predicted (FVC%): 68.9% +/- 14.4 vs. 73.0% +/- 17.7, p < 0.05; Total lung 
      capacity, % of predicted (TLC%): 62.2% +/- 11.8 vs. 68.6% +/- 11.3%, p < 0.001) were 
      significantly different at presentation between males and females, respectively. 
      Comorbidities such as coronary artery disease (OR: 3.5-95% CI: 1.6-7.6) and other 
      cardiovascular diseases (including atrial fibrillation and heart failure) (OR: 
      3.8-95% CI: 1.9-7.8) also showed significant differences between the genders. The 
      K- BILD showed poor quality of life, but no difference was found between genders 
      in total score (54 +/- 11 vs. 54 +/- 10, p = 0.61 in males vs. females, 
      respectively). CONCLUSIONS: This study shows that female patients with IPF have a 
      more preserved lung function than males at inclusion, while males have a 
      significant burden of cardiovascular comorbidities. However, QoL and results on 
      the 6MWT did not differ between the groups. These gender differences may be of 
      importance both at diagnosis and follow- up of patients with IPF.
FAU - Kalafatis, Dimitrios
AU  - Kalafatis D
AD  - Respiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Gao, Jing
AU  - Gao J
AD  - Respiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
      Stockholm, Sweden.
FAU - Pesonen, Ida
AU  - Pesonen I
AD  - Respiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Respiratory Medicine and Allergy, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Carlson, Lisa
AU  - Carlson L
AD  - Respiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Respiratory Medicine and Allergy, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Skold, C Magnus
AU  - Skold CM
AD  - Respiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
      Stockholm, Sweden.
AD  - Department of Respiratory Medicine and Allergy, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Ferrara, Giovanni
AU  - Ferrara G
AUID- ORCID: 0000-0002-3807-3315
AD  - Respiratory Medicine Unit, Department of Medicine Solna, Karolinska Institutet, 
      Stockholm, Sweden. Giovanni.Ferrara@ki.se.
AD  - Department of Respiratory Medicine and Allergy, Karolinska University Hospital, 
      Stockholm, Sweden. Giovanni.Ferrara@ki.se.
LA  - eng
GR  - 20180660/Hjart-Lungfonden/
PT  - Journal Article
DEP - 20191127
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Cohort Studies
MH  - Comorbidity
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Idiopathic Pulmonary Fibrosis/*epidemiology/*physiopathology
MH  - Lung/*physiopathology
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - *Quality of Life
MH  - Registries
MH  - Regression Analysis
MH  - *Sex Factors
MH  - Sweden/epidemiology
MH  - Total Lung Capacity
MH  - Vital Capacity
PMC - PMC6880431
OTO - NOTNLM
OT  - Comorbidities
OT  - Gender perspective
OT  - Idiopathic pulmonary fibrosis
OT  - Interstitial lung disease
OT  - KBILD
OT  - Registry
COIS- DK and JG reports no conflict of interest. IP received fees for lectures from 
      Boehringer Ingelheim and Roche. LC received fees for lectures from Boehringer 
      Ingelheim and Roche. MS received fees for lectures and consulting from Boehringer 
      Ingelheim and Roche. GF received fees for lectures from Boehringer Ingelheim and 
      Roche.
EDAT- 2019/11/28 06:00
MHDA- 2020/04/30 06:00
PMCR- 2019/11/27
CRDT- 2019/11/28 06:00
PHST- 2019/04/23 00:00 [received]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2019/11/28 06:00 [entrez]
PHST- 2019/11/28 06:00 [pubmed]
PHST- 2020/04/30 06:00 [medline]
PHST- 2019/11/27 00:00 [pmc-release]
AID - 10.1186/s12890-019-0994-4 [pii]
AID - 994 [pii]
AID - 10.1186/s12890-019-0994-4 [doi]
PST - epublish
SO  - BMC Pulm Med. 2019 Nov 27;19(1):222. doi: 10.1186/s12890-019-0994-4.